Healthy Adult ParticipantsSPARCNCT07419100
Sedentary Behaviour, Physical Activity Patterns, and Cardiometabolic Health
A study testing Continuous moderate intensity physical activity, Light-intensity physical activity breaks and High-intensity physical activity breaks in people with Healthy Adult Participants, run by Hasselt University at 1 site in Belgium.
Trial summary
According to the World Health Organization (WHO), chronic diseases are a major global public health concern and the leading cause of mortality worldwide. In the absence of evidence-based actions, the global annual deaths from chronic diseases are projected to rise to 55 million deaths in 2030, accompanied by a… Read more about this study
- Who is it for?
- Ages 40 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Adult Participants
- What is being tested?
- Continuous moderate intensity physical activity, Light-intensity physical activity breaks and High-intensity physical activity breaks
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 48 participants
- Where
- 1 siteBelgium
- Study dates
- 1 Mar 2026to 1 Jun 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults aged 40-70 years
- Sedentary (>9 hours per day)
- < 3 exercise sessions per week
Who cannot join
- Pregnancy or intend to become pregnant
- Any known contra-indications for physical activity
- >14 alcohol consumptions per week for women and >20 alcohol consumptions per week for men
- Involved in a weight reduction program with an energy restriction diet during the study period
- No consistent body weight over the past month
- Diagnosed with any known cardiometabolic health-related disease
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Bert Op 't Eijnde, PhD contact
Belgium1 site
Hasselt University
Diepenbeek, Limburg, 3590
Bert Op 't Eijnde, PhD, bert.opteijnde@uhasselt.be
Wouter Franssen, PhD, wouter.franssen@uhasselt.be
About this study
Official title: From Sitting to Moving: How Physical Activity Patterns Can Reduce Sedentary Behaviour and Support Cardiometabolic Health
According to the World Health Organization (WHO), chronic diseases are a major global public health concern and the leading cause of mortality worldwide. In the absence of evidence-based actions, the global annual deaths from chronic diseases are projected to rise to 55 million deaths in 2030, accompanied by a substantial increase in socio-economic costs. In this context, the WHO identifies type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVD) as key chronic conditions of concern related to cardiometabolic health.
Both sedentary behaviour (SB) and physical inactivity have been recognised as interdependent risk factors for the development of T2DM and CVD. SB refers to any waking behaviour, characterised by a low energy expenditure, while being in a sitting or reclining posture, whereas physical inactivity denotes insufficient levels (<150 min per week,) of moderate-to-vigorous physical activity (MVPA). Studies using objective measures have demonstrated that on average Western adults spend 8-12h in SB per day, of which the majority is spent in prolonged sedentary bouts (lasting ≥30 min). In addition, up to 30% of adults worldwide are physically inactive, with higher levels of inactivity in high-income countries. Within this context, it has become evident that excessive prolonged SB, often in combination with physical inactivity, negatively impacts cardiometabolic health, contributing to insulin resistance, increased adiposity, poor lipid profiles and endothelial dysfunction. Given their detrimental effects on T2DM and CVD, strategies aimed at reducing SB and promoting physical activity (PA) warrant further investigation.
Read more
Reducing and regularly interrupting SB, even with low-intensity PA, alongside sufficient MVPA, is crucial for maintaining a healthy cardiometabolic profile. Reflecting this, the WHO guidelines advise individuals to engage in 150-300 minutes of moderate-intensity physical activity, 75-150 minutes of vigorous-intensity physical activity, or an equivalent combination each week. Notably, the 2020 WHO guidelines also included recommendations on SB for the first time, emphasizing the importance of limiting sedentary time. The WHO states that replacing SB with physical activity of any intensity can yield health benefits. However, these recommendations remain non-prescriptive and somewhat vague, primarily due to a lack of robust scientific evidence on the optimal frequency, intensity, and duration of PA needed to interrupt sedentary time. The absence of specific guidelines on prolonged SB reflects this evidence gap. To support policy development, well-designed randomised controlled trials are needed to evaluate effective and practical strategies for reducing sedentary time.
So far, the short term cardiometabolic health effects of SB interruptions have been investigated by our research group, laboratory studies of collaborators and other international researchers, demonstrating that; 1) more frequent SB interruptions especially affect glucose metabolism and insulin sensitivity; 2) higher intensity interruptions are associated with cardioprotective adaptations and; 3) longer durations of SB interruptions positively affect lipid metabolism. However, because under real-world conditions frequency, intensity and duration of SB interruptions usually interact, their combined effects on cardiometabolic health need further investigation. Many studies already compared the isolated effects of different SB interruption patterns with respect to frequency, duration and intensity on cardiometabolic health. However, the combined effects of these different approaches matched for energy expenditure are not clear yet. We therefore perform a balanced cross-over study in which the efficacy of distinct activity patterns on cardiometabolic health insulin sensitivity and vascular function) will be compared to a sedentary control condition.
- Conditions
- Healthy Adult Participants
- Being tested
- Continuous moderate intensity physical activity, Light-intensity physical activity breaks, High-intensity physical activity breaks
- Keywords
- Physical Activity, Intensity, Frequency, Duration, Cardiometabolic health
- Medical subject headings
- Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Continuous moderate intensity physical activityBehavioural
One continuous physical activity bout of moderate intensity will be performed during the 6 hour testing day.
Light-intensity physical activity breaksBehavioural
Light-intensity physical activity breaks every 30 minutes during the 6 hour testing day.
High-intensity physical activity breaksBehavioural
High-intensity physical activity breaks every 30 minutes during the 6 hour testing day.
| Study group | Role | What they receive |
|---|---|---|
| Control | No intervention | Prolonged sitting for 6 hours |
| Continuous moderate intensity physical activity | Experimental | One continuous physical activity bout of moderate intensity will be performed during the 6 hour testing day. Receives: Behavioral: Continuous moderate intensity physical activity |
| Continuous moderate intensity physical activity + light-intensity physical activity breaks | Experimental | One continuous physical activity bout of moderate intensity will be combined with light-intensity physical activity breaks every 30 minutes during the 6 hour testing day. Receives: Behavioral: Continuous moderate intensity physical activity; Behavioral: Light-intensity physical activity breaks |
| Continuous moderate intensity physical activity + high-intensity physical activity breaks | Experimental | One continuous physical activity bout of moderate intensity will be combined with high-intensity physical activity breaks every 30 minutes during the 6 hour testing day. Receives: Behavioral: Continuous moderate intensity physical activity; Behavioral: High-intensity physical activity breaks |
| Light-intensity physical activity breaks | Experimental | Prolonged sitting will be interrupted by light-intensity physical activity breaks every 30 minutes during the 6-hour testing day. Receives: Behavioral: Light-intensity physical activity breaks |
| High-intensity physical activity breaks | Experimental | Prolonged sitting will be interrupted by high-intensity physical activity breaks every 30 minutes during the 6-hour testing day. Receives: Behavioral: High-intensity physical activity breaks |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total and incremental area under the curve of postprandial insulin response
Insulin concentrations will be assessed in serum samples at nine time points over the 6-hour testing period. Postprandial responses will be quantified as the area under the curve (AUC) across the six-hour period.
Measured: Blood samples will be collected at 0, 30, 60, 120, 180, 210, 240, 300, and 360 minutes during the 6-hour testing day.
Vascular endothelial function
Vascular endothelial function will be assessed by flow-mediated dilation (FMD) according to published guidelines. These measurements take place at 8 a.m. and involve doppler ultrasound imaging of the superficial femoral artery. A cuff will be placed on the right lower leg, and the superficial femoral artery is imaged longitudinally. FMD will be measured at baseline and after a 5-min occlusion phase (reactive hyperaemia response). FMD will be quantified as the percentage difference between peak and baseline diameter (FMD%).
Measured: FMD measurement will be performed at the start (08:30 a.m.) and after 6 hours (2:30 p.m.) of the testing day.
Secondary outcomes (14)
Cardiorespiratory Fitness
Cardiorespiratory fitness will be measured as peak oxygen consumption (V̇O2peak) using a graded cardiopulmonary exercise test (CPET) on a bike with pulmonary gas exchange analysis (Metalyzer IIIb) until volitional exhaustion.
Measured: Baseline measurement
Sedentary time
Sedentary time will be quantified using the activPAL3™ activity monitor.
Measured: Measured for 7 consecutive days after the screening visit
Body mass index
Body mass index (BMI; kg/m²) is calculated from weight and height measurements (weight/height²).
Measured: Baseline measurement
Moderate-to-vigorous physical activity
Moderate-to-vigorous physical activity will be quantified using the activPAL3™ activity monitor.
Measured: Measured for 7 consecutive days after the screening visit
Body weight
Body weight (in underwear) is determined using a digital-balanced weighting scale to the nearest 0.1kg.
Measured: Baseline measurement
High-density lipoprotein cholesterol concentration
High-density lipoprotein cholesterol concentration will be measured in fasting plasma samples
Measured: Blood samples will be taken at the beginning of the testing day (8 a.m.).
Total cholesterol concentration
Total cholesterol concentration will be measured in fasting plasma samples
Measured: Blood samples will be taken at the beginning of the testing day (8 a.m.).
Total and incremental area under the curve of postprandial glucose response
Glucose concentrations will be assessed in plasma samples at nine time points over the 6-hour testing period. Postprandial responses will be quantified as the area under the curve (AUC) across the six-hour period.
Measured: Blood samples will be collected at 0, 30, 60, 120, 180, 210, 240, 300, and 360 minutes during the 6-hour testing day.
Total and incremental area under the curve of postprandial insulin response
Triglyceride concentrations will be assessed in plasma samples at nine time points over the 6-hour testing period. Postprandial responses will be quantified as the area under the curve (AUC) across the six-hour period.
Measured: Blood samples will be collected at 0, 30, 60, 120, 180, 210, 240, 300, and 360 minutes during the 6-hour testing day.
Peak heart rate
Peak heart rate assessed during cardiopulmonary exercise testing
Measured: Baseline measurement
Blood pressure
After an initial resting period of 10 min with participants in a supine position in a quiet room with constant temperature (21°C), systolic and diastolic blood pressure (BP; in mmHg) will be measured at least 3 times at 2-min intervals until BP is stable using an electronic sphygmomanometer (Omron®) from the left arm and documented as the mean value of the three final measurements.
Measured: Blood pressure will be measured during the screening visit, and hourly at 0, 60, 120, 180, 240, 300, and 360 minutes during the 6-hour testing day.
Body fat percentage
Percentage body fat will be evaluated using Dual Energy X-ray Absorptiometry.
Measured: Baseline measurement
Low-density lipoprotein cholesterol concentration
Low-density lipoprotein cholesterol concentration will be measured in fasting plasma samples
Measured: Blood samples will be taken at the beginning of the testing day (8 a.m.).
Waist circumference
Measured: Baseline measurement
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Feb 2026
- Study start1 Mar 2026 (estimated)
- Primary completion1 Jun 2028 (estimated)
- Study completion1 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy Adult ParticipantsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Incomplete block design
- Masking
- None (open label)
- Enrolment
- 48 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hasselt University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Bert Op't Eijnde, Hasselt University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07419100
- Sponsor's protocol ID
- CME2025/100
- Acronym
- SPARC
- Status last verified
- Feb 2026
- First submitted
- 3 Feb 2026
- Last updated
- 18 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- From Sitting to Moving: How Physical Activity Patterns Can Reduce Sedentary Behaviour and Support Cardiometabolic Health
- ClinicalTrials.gov ID
- NCT07419100
- Acronym / sponsor ID
- SPARC / CME2025/100
- Conditions
- Healthy Adult Participants
- Keywords
- Physical Activity, Intensity, Frequency, Duration, Cardiometabolic health
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 48 participants (estimated)
- Lead sponsor
- Hasselt UniversityUniversity, hospital or other
- Study start
- 1 Mar 2026 (estimated)
- Primary completion
- 1 Jun 2028 (estimated)
- Study completion
- 1 Jun 2028 (estimated)
- First posted
- 18 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
According to the World Health Organization (WHO), chronic diseases are a major global public health concern and the leading cause of mortality worldwide. In the absence of evidence-based actions, the global annual deaths from chronic diseases are projected to rise to 55 million deaths in 2030, accompanied by a substantial increase in socio-economic costs. In this context, the WHO identifies type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVD) as key chronic conditions of concern related to cardiometabolic health.
Both sedentary behaviour (SB) and physical inactivity have been recognised as interdependent risk factors for the development of T2DM and CVD. SB refers to any waking behaviour, characterised by a low energy expenditure, while being in a sitting or reclining posture, whereas physical inactivity denotes insufficient levels (<150 min per week,) of moderate-to-vigorous physical activity (MVPA). Studies using objective measures have demonstrated that on average Western adults spend 8-12h in SB per day, of which the majority is spent in prolonged sedentary bouts (lasting ≥30 min). In addition, up to 30% of adults worldwide are physically inactive, with higher levels of inactivity in high-income countries. Within this context, it has become evident that excessive prolonged SB, often in combination with physical inactivity, negatively impacts cardiometabolic health, contributing to insulin resistance, increased adiposity, poor lipid profiles and endothelial dysfunction. Given their detrimental effects on T2DM and CVD, strategies aimed at reducing SB and promoting physical activity (PA) warrant further investigation.
Reducing and regularly interrupting SB, even with low-intensity PA, alongside sufficient MVPA, is crucial for maintaining a healthy cardiometabolic profile. Reflecting this, the WHO guidelines advise individuals to engage in 150-300 minutes of moderate-intensity physical activity, 75-150 minutes of vigorous-intensity physical activity, or an equivalent combination each week. Notably, the 2020 WHO guidelines also included recommendations on SB for the first time, emphasizing the importance of limiting sedentary time. The WHO states that replacing SB with physical activity of any intensity can yield health benefits. However, these recommendations remain non-prescriptive and somewhat vague, primarily due to a lack of robust scientific evidence on the optimal frequency, intensity, and duration of PA needed to interrupt sedentary time. The absence of specific guidelines on prolonged SB reflects this evidence gap. To support policy development, well-designed randomised controlled trials are needed to evaluate effective and practical strategies for reducing sedentary time.
So far, the short term cardiometabolic health effects of SB interruptions have been investigated by our research group, laboratory studies of collaborators and other international researchers, demonstrating that; 1) more frequent SB interruptions especially affect glucose metabolism and insulin sensitivity; 2) higher intensity interruptions are associated with cardioprotective adaptations and; 3) longer durations of SB interruptions positively affect lipid metabolism. However, because under real-world conditions frequency, intensity and duration of SB interruptions usually interact, their combined effects on cardiometabolic health need further investigation. Many studies already compared the isolated effects of different SB interruption patterns with respect to frequency, duration and intensity on cardiometabolic health. However, the combined effects of these different approaches matched for energy expenditure are not clear yet. We therefore perform a balanced cross-over study in which the efficacy of distinct activity patterns on cardiometabolic health insulin sensitivity and vascular function) will be compared to a sedentary control condition.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 6
- Model description
- Incomplete block design
| Arm | Type | Receives |
|---|---|---|
| Control | No intervention | –Prolonged sitting for 6 hours |
| Continuous moderate intensity physical activity | Experimental | Behavioral: Continuous moderate intensity physical activityOne continuous physical activity bout of moderate intensity will be performed during the 6 hour testing day. |
| Continuous moderate intensity physical activity + light-intensity physical activity breaks | Experimental | Behavioral: Continuous moderate intensity physical activity, Behavioral: Light-intensity physical activity breaksOne continuous physical activity bout of moderate intensity will be combined with light-intensity physical activity breaks every 30 minutes during the 6 hour testing day. |
| Continuous moderate intensity physical activity + high-intensity physical activity breaks | Experimental | Behavioral: Continuous moderate intensity physical activity, Behavioral: High-intensity physical activity breaksOne continuous physical activity bout of moderate intensity will be combined with high-intensity physical activity breaks every 30 minutes during the 6 hour testing day. |
| Light-intensity physical activity breaks | Experimental | Behavioral: Light-intensity physical activity breaksProlonged sitting will be interrupted by light-intensity physical activity breaks every 30 minutes during the 6-hour testing day. |
| High-intensity physical activity breaks | Experimental | Behavioral: High-intensity physical activity breaksProlonged sitting will be interrupted by high-intensity physical activity breaks every 30 minutes during the 6-hour testing day. |
Who may qualify
- Ages
- 40 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Adults aged 40-70 years
- Sedentary (>9 hours per day)
- < 3 exercise sessions per week
Key exclusion criteria (6 listed)
- Pregnancy or intend to become pregnant
- Any known contra-indications for physical activity
- >14 alcohol consumptions per week for women and >20 alcohol consumptions per week for men
- Involved in a weight reduction program with an energy restriction diet during the study period
- No consistent body weight over the past month
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Continuous moderate intensity physical activityOne continuous physical activity bout of moderate intensity will be performed during the 6 hour testing day. | Behavioural | Continuous moderate intensity physical activity, Continuous moderate intensity physical activity + high-intensity physical activity breaks, Continuous moderate intensity physical activity + light-intensity physical activity breaks |
| Light-intensity physical activity breaksLight-intensity physical activity breaks every 30 minutes during the 6 hour testing day. | Behavioural | Continuous moderate intensity physical activity + light-intensity physical activity breaks, Light-intensity physical activity breaks |
| High-intensity physical activity breaksHigh-intensity physical activity breaks every 30 minutes during the 6 hour testing day. | Behavioural | Continuous moderate intensity physical activity + high-intensity physical activity breaks, High-intensity physical activity breaks |
Primary outcome
Total and incremental area under the curve of postprandial insulin response
Time frame: Blood samples will be collected at 0, 30, 60, 120, 180, 210, 240, 300, and 360 minutes during the 6-hour testing day.
Insulin concentrations will be assessed in serum samples at nine time points over the 6-hour testing period. Postprandial responses will be quantified as the area under the curve (AUC) across the six-hour period.
Vascular endothelial function
Time frame: FMD measurement will be performed at the start (08:30 a.m.) and after 6 hours (2:30 p.m.) of the testing day.
Vascular endothelial function will be assessed by flow-mediated dilation (FMD) according to published guidelines. These measurements take place at 8 a.m. and involve doppler ultrasound imaging of the superficial femoral artery. A cuff will be placed on the right lower leg, and the superficial femoral artery is imaged longitudinally. FMD will be measured at baseline and after a 5-min occlusion phase (reactive hyperaemia response). FMD will be quantified as the percentage difference between peak and baseline diameter (FMD%).
14 secondary outcomes
Cardiorespiratory Fitness
Time frame: Baseline measurement
Sedentary time
Time frame: Measured for 7 consecutive days after the screening visit
Body mass index
Time frame: Baseline measurement
Moderate-to-vigorous physical activity
Time frame: Measured for 7 consecutive days after the screening visit
Body weight
Time frame: Baseline measurement
High-density lipoprotein cholesterol concentration
Time frame: Blood samples will be taken at the beginning of the testing day (8 a.m.).
Total cholesterol concentration
Time frame: Blood samples will be taken at the beginning of the testing day (8 a.m.).
Total and incremental area under the curve of postprandial glucose response
Time frame: Blood samples will be collected at 0, 30, 60, 120, 180, 210, 240, 300, and 360 minutes during the 6-hour testing day.
Total and incremental area under the curve of postprandial insulin response
Time frame: Blood samples will be collected at 0, 30, 60, 120, 180, 210, 240, 300, and 360 minutes during the 6-hour testing day.
Peak heart rate
Time frame: Baseline measurement
Blood pressure
Time frame: Blood pressure will be measured during the screening visit, and hourly at 0, 60, 120, 180, 240, 300, and 360 minutes during the 6-hour testing day.
Body fat percentage
Time frame: Baseline measurement
Low-density lipoprotein cholesterol concentration
Time frame: Blood samples will be taken at the beginning of the testing day (8 a.m.).
Waist circumference
Time frame: Baseline measurement
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Feb 2026.
Related trials for Healthy Adult Participants
RecruitingPhase 4
Age-Associated Differences in Germinal Center Responses to Influenza and Rabies Vaccination in Humans
Healthy Adult Participants, Age 65 and Older
RecruitingPhase 1
A Study to Assess the Relative Bioavailability of Irafamdastat (BMS-986368) and to Assess the Food Effect on the Pharmacokinetics of Irafamdastat in Healthy Adult Participants
Healthy Volunteers
RecruitingPhase 1
A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma
Healthy Volunteer Study, Healthy Adults
Not yet recruitingPhase 1
Safety, Tolerability and Pharmacokinetics of ICP-B161 in Healthy Adults Volunteers
Inflammatory Bowel Disease(IBD)
Not yet recruitingPhase 1
Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation
Psoriasis, Arthritis, Psoriatic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Bert Op 't Eijnde, PhD contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Continuous moderate intensity physical activity, Light-intensity physical activity breaks and High-intensity physical activity breaks in people with Healthy Adult Participants, run by Hasselt University at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 18 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Wouter Franssen, PhD (+32(0)11 29 21 29, wouter.franssen@uhasselt.be), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total and incremental area under the curve of postprandial insulin response (time frame: Blood samples will be collected at 0, 30, 60, 120, 180, 210, 240, 300, and 360 minutes during the 6-hour testing day.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2026.